Lisa Lanning, DO
Family Medicine · Baker City, ORNPI 1023207784
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 90 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Novo Nordisk at 26.7% of the total. Reporting peaked in 2019 at $591 and has fallen 97.6% since, to $14 in 2024. Among family medicine clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 90 payments — averaging $16.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$392
- Lilly USA, LLC$259
- GSK$113
- AbbVie$97
- Amgen$93
- Johnson & Johnson$70
- plus $442 from 15 others
What the payments were for
- Food & beverage$1,43598%
- Education$322%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 20 | $392 |
| Lilly USA, LLC | 17 | $259 |
| GSK | 7 | $113 |
| AbbVie | 6 | $97 |
| Amgen(2 entities) | 7 | $93 |
| Johnson & Johnson | 6 | $70 |
| Novartis | 4 | $69 |
| Gilead | 1 | $57 |
| AstraZeneca | 4 | $57 |
| Pfizer | 3 | $43 |
| E.r. Squibb & Sons, L.L.C. | 3 | $41 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Merck | 2 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Cvrx, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $12 |
| Hikma Pharmaceuticals USA | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
How this compares
$1,467 in reported general payments places this provider in the 90th percentile of 1,221 family medicine providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 46 | $32,731 |
| TrulicityDulaglutide | 25 | $27,882 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $20,864 |
| OzempicSemaglutide | 13 | $20,266 |
| JardianceEmpagliflozin | 12 | $17,566 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 16 | $10,427 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $7,417 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $2,798 |
| Varenicline Tartrate | 11 | $2,672 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 52 | $1,646 |
| Ventolin HfaAlbuterol Sulfate | 17 | $1,423 |
| Pregabalin | 21 | $1,386 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $1,290 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 71 | $1,278 |
| Gabapentin | 82 | $1,270 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $43 | $32,73146 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $113 | $28,28145 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $12 | $27,99228 claims |
| Lilly USA, LLCTrulicity | $259 | $27,88225 claims |
| Novo NordiskOzempic | $392 | $20,26613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,221 family medicine providers in Oregon.
Other family medicine in Baker City
- Eden MillerBend$1.7M
- Anil RajaniHood River$325K
- Stephen NelsonMedford$101K
- Karen KahnAshland$86K
- Robert GobboPortland$53K
- Kevin MillerSisters$39K
- Morris MaizelsCentral Point$25K
- Maureen MaysPortland$24K
- Nathaniel FondellMedford$21K
- Carl EricksonMilwaukie$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.